Month: October 2021

New Duke University-led Study Shows That Vaxart’s Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model

10/12/2021

Data published in bioRxiv confirmed previous findings suggesting mucosal vaccines could reduce transmission of airborne viruses such as COVID-19 and flu more than injectable vaccinesStudy suggests mucosal vaccines may protect not only vaccinated, but also unvaccinated animals Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 /PRNewswire/ — A Duke University-led study published in bioRxiv showed that Vaxart,…

Read More

Limbix Launches First Digital Therapeutic for Adolescents with Symptoms of Depression

10/12/2021

Program delivered on smartphone is based on core principles of cognitive behavioral therapy, with focus on behavioral activation Trial results demonstrate clinically meaningful reduction in depression symptoms Completing SparkRx as recommended results in statistically significant reduction in symptoms compared to control Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Today, Limbix, a prescription digital therapeutic company developing…

Read More

India’s Bharat Biotech submits data on COVID-19 drug trial in children

10/11/2021

Excerpt from the Press Release: BENGALURU, Oct 6 (Reuters) – Bharat Biotech said on Wednesday it had submitted data from its COVID-19 vaccine trial in children aged 2 to 18 years to India’s drug regulator, becoming the country’s first company to have tested its shot in very young children. The South Asian country is turning…

Read More

Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc.

10/11/2021

Acquisition to add new left heart access platforms to electrophysiology and structural heart portfolios Excerpt from the Press Release: MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to…

Read More

Protecting cancer patients from COVID-19: world-first clinical trial tests a novel immune-boosting strategy

10/11/2021

Excerpt from the Press Release In the race to find new ways to prevent and treat COVID-19, OICR-supported researchers have launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. The trial involves IMM-101, a preparation of safe, heat-killed bacteria that broadly stimulates the…

Read More

Kinetic River Corp. Receives First Japanese Patent for Time-Resolved Flow Cytometry

10/08/2021

This issuance expands global protection for Kinetic River’s technologies aimed at expanding the power of flow cytometry Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Oct. 1, 2021 /PRNewswire/ — Kinetic River Corp., a leader in custom flow cytometry instrumentation, announced today having been issued a patent from the Japanese Patent Office covering its innovative technologies…

Read More

Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting

10/08/2021

Excerpt from the Press Release: LYON, France and CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from its Phase 1 clinical trial of AZP-3601, a potential treatment for hypoparathyroidism, at the American Society for Bone…

Read More

Inflammasome Therapeutics’ Kamuvudines Continue to Show Promise for Future Treatment – and Potentially a Cure – for Blindness in Seniors

10/07/2021

New research published today in Science Advances describes precise mechanism of how Alu reverse transcription occurs from RNA to cDNA, and its subsequent triggering of inflammasome activation and consequent cell death in Geographic Atrophy (GA) – the most severe form of dry age-related macular degeneration. Research shows Alu RNA/cDNA reverse transcription confined to rim of…

Read More

Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial

10/07/2021

Excerpt from the Press Release: MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) — Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. (“Apollomics”), an innovative biopharmaceutical company committed to the discovery and development of mono- and…

Read More

Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors

10/07/2021

Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, Sept. 29, 2021 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced a phase I/II clinical study of KRAS G12C inhibitor IBI351…

Read More